ISW Holdings Announces 5M Share Stock Option Plan to Add Key Talent in Front of Major Catalysts

LAS VEGAS, NV, Dec. 23, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a global brand management holdings company, is excited to announce the creation of a new stock option compensation plan in anticipation of the establishment of an advisory board and the addition of new top team members to help the Company optimize its execution as it navigates new and increasingly promising opportunities.

The Company has recently made a number of advances that management believes will help attract top talent interested in joining a growing enterprise, including:

  • Elimination of $702,000 in convertible debt
  • Reduction of outstanding shares by nearly 15% 
  • Reduction in authorized shares to just 60 million
  • Assembly, shipment, & green-lighting of Pod5 high-efficiency cryptocurrency mining pod
  • On pace for 7th consecutive quarter of sequential growth in revenues
  • On pace for new Company record financial performance in 2020

“We have set aside 5 million shares for this incentive program,” said Alonzo Pierce, President and Chairman of ISW Holdings. “We have made significant progress towards accomplishing our strategic goals this year and implementing our long-term business plan.”

The Company’s advisory board will consist of experienced leaders with credible track records of successful execution in telehealth, healthcare manufacturing, and blockchain (Bitcoin software development, node projects, Bitcoin education, and start-up advisory and hosting).

The members of the Company advisory board will be introduced to the public in January.

“This new program will allow us to retain our top performers and appeal to an increasingly competitive class of talent,” Pierce said. “We are looking for the best and brightest technology engineers, cryptocurrency mining operators, and financial executives and advisors with the experience and acumen to take this Company to the next level.”

About ISW Holdings

ISW Holdings, Inc. (ISWH), based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. Our expertise lies in strategic brand development, early growth facilitation, as well as brand identity through our proprietary procurement process. Together, with our partners, we seek to provide a structure that meets large scalability demands, as well as anticipated marketplace needs. We are able to meet these needs through a variety of strategic innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; and the partnership has a vitally needed patent now pending.

Forward Looking Statements

This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including “could”, “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential” and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company’s reports filed from time to time with OTC Markets (www.otcmarkets.com).

For more information, visit www.iswholdings.com

Company Contact:

Investor Relations

[email protected]



Bespoke Extracts Welcomes Mixed Martial Artists Paige VanZant and Austin Vanderford to the Growing Team of Bespoke CBD Brand Ambassadors

SUNNY ISLES, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) — Bespoke Extracts, Inc. (OTC Pink: BSPK), producer of high quality, hemp-derived CBD products, today welcomed husband-wife professional mixed martial artists (MMA) Austin Vanderford and Paige VanZant to its fast growing team of Bespoke CBD brand ambassadors.

A mixed martial artist, author and professional model, VanZant has won a global following of adoring fans due to her success in the flyweight division of the Ultimate Fighting Championship (UFC), finishing second place during one season of “Dancing with the Stars,” and winning the Food Network’s celebrity cooking championship on “Chopped,” among many other prolific accomplishments. In August of this year, she signed a contract to fight exclusively in the Bare Knuckle Fighting Championship with her first bout scheduled to take place in February 2021 during Super Bowl weekend.

Married to VanZant since September 2018, professional MMA middleweight fighter Austin “The Gentleman” Vanderford boasts an undefeated record in the cage at 10-0. Prior to fighting for Bellator MMA where his record currently stands at 4-0, Vanderford went undefeated at 6-0 with the UFC. Together, VanZant and Vanderford have more than three million followers on Instagram and another one million plus on Facebook.  

Danny Pollack, Bespoke Extracts CEO, stated, “As elite professional athletes and inspiring personalities with millions of fans and followers, the social influence and brand validation that Austin and Paige are bringing to bear for Bespoke CBD products is expected to have measurable impact on our Company’s global brand awareness and promising growth potential.”

Vanderford noted, “Paige and I both value the importance of maintaining optimal health and wellness so that we can attain our high performance goals – both in and out of the cage. Bespoke’s premium, all-natural, hemp-derived CBD products play an important role in helping us to look and feel our best, so agreeing to become brand ambassadors for Bespoke was a no-brainer for us.”

“I rely on my body for my livelihood, so I only buy and use products from brands, like Bespoke, which value my health and wellness as much as I do. Austin and I are very proud to become Bespoke brand ambassadors and look forward to spreading the word on how Bespoke CBD is having a positive impact on our wellness,” added VanZant.

About Bespoke Extracts, Inc.

At Bespoke Extracts, we believe in the power of the individual. So, we strive to tailor each CBD experience to make its benefits unique to you and your lifestyle. That means making sure you are confident that everything we deliver to you is safe, effective, and perfect for you. From the very beginning, we have hand-picked our producers to ensure only NSF-certified and USDA-certified organic hemp from some of the finest CBD growers in the United States. It is also why we use the industry standard for extraction to ensure the purest and most potent product on the market. And finally, it’s why we strive to develop a long-term personal relationship with each and every one of our customers—including you—to help them determine their needs and wants and supply the exact right solution for them. For more information, please visit www.bespokeextracts.com.  

FORWARD-LOOKING STATEMENT

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to our competitive position, the industry environment, potential growth opportunities, and the effects of regulation and events outside of our control, such as natural disasters, wars or health epidemics. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

No statement in this press release has been evaluated by the Food and Drug Administration. The efficacy of Bespoke’s products has not been confirmed by FDA-approved research. Our products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your health care professional about potential interactions or other possible complications before using any Bespoke Extract product. Bespoke Extracts, Inc. shall not be held liable for any medical claims made by customer testimonials.

For more information, please contact:

Bespoke Extracts, Inc.

Phone: 888-575-6738
Email: [email protected]
Web:  www.bespokeextracts.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2578ddd5-80b6-4a2b-98ab-c534bbbee85a



/C O R R E C T I O N from Source — Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions/

Canada NewsWire

In the news release, IIROC Trading Resumption – GRAT, issued 22-Dec-2020 by Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions over CNW, we are advised by the company that the date of the resumption should have read 12/23/2020 rather than 12/24/2020 as originally issued inadvertently. The complete, corrected release follows:

IIROC Trading Resumption – GRAT

VANCOUVER, BC, Dec. 22, 2020 /CNW/ – Trading resumes in:

Company: Gratomic Inc.

TSX-Venture Symbol: GRAT

All Issues: No

Resumption (ET): 8:00 AM 12/23/2020

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

AG Mortgage Investment Trust, Inc. Announces Fourth Quarter 2020 Common Dividend of $0.03 per Share

AG Mortgage Investment Trust, Inc. Announces Fourth Quarter 2020 Common Dividend of $0.03 per Share

NEW YORK–(BUSINESS WIRE)–
AG Mortgage Investment Trust, Inc. (NYSE: MITT) announced that its Board of Directors has declared a dividend of $0.03 per common share for the fourth quarter 2020. The dividend is payable on January 29, 2021 to shareholders of record at the close of business on December 31, 2020.

About AG Mortgage Investment Trust, Inc.

AG Mortgage Investment Trust, Inc. is a hybrid mortgage REIT that opportunistically invests in and manages a diversified risk-adjusted portfolio of Agency RMBS and Credit Investments. Its Credit Investments include Residential Investments and Commercial Investments. AG Mortgage Investment Trust, Inc. is externally managed and advised by AG REIT Management, LLC, a subsidiary of Angelo, Gordon & Co., L.P., an SEC-registered investment adviser that specializes in alternative investment activities.

Additional information can be found on the Company’s website at www.agmit.com.

About Angelo Gordon

Angelo, Gordon & Co., L.P. is a privately held limited partnership founded in November 1988. The firm manages approximately $41 billion as of September 30, 2020 with a primary focus on credit and real estate strategies. Angelo Gordon has over 550 employees, including more than 200 investment professionals, and is headquartered in New York, with offices in the U.S., Europe and Asia. For more information, visit www.angelogordon.com.

AG Mortgage Investment Trust, Inc.

Investor Relations

(212) 692-2110

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.

The shares of common stock in the public offering were offered pursuant to a registration statement on Form S-3 (File No. 333-244362), which was declared effective by the Securities and Exchange Commission (SEC) on August 20, 2020. The public offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and the accompanying prospectus relating to the public offering will be filed by the Company with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by telephone at (212) 667-8055, or by email at [email protected].

In a separate concurrent private placement transaction led by healthcare-focused institutional investors, Cellectar offered and sold 1,518.5180 shares of Series D convertible preferred stock convertible into a number of shares of common stock equal to $13,500 divided by $1.35 (the “Conversion Price”) (or 10,000 shares of common stock for each share of Series D Preferred Stock converted), at a price of $13,500 per share of Series D Preferred Stock. The gross proceeds from the private placement are expected to be approximately $20.5 million, prior to deducting placement agent fees and estimated expenses. The Series D Preferred Stock will only be convertible into common stock upon receipt of stockholder approval of the issuance of the shares of common stock as required by Nasdaq Marketplace Rule 5635(d) at a special stockholder meeting to be called for that purpose. The Series D Preferred Stock and the shares of our common stock issuable upon the exercise of the Series D Preferred Stock are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. Such preferred shares and common shares issuable upon conversion of the preferred shares have not been registered under the Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

Oppenheimer & Co. Inc. acted as the sole book-running manager in connection with the public offering and the lead placement agent in connection with the private placement. Roth Capital Partners, Maxim Group LLC and Ladenburg Thalmann & Co. Inc. acted as co-managers in connection with the public offering and as co-placement agents in connection with the private placement.

The public offering and the private placement are expected to close on or about December 28, 2020, subject to the satisfaction or waiver of customary closing conditions.

This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Cellectar being offered in the public offering or concurrent private placement, and shall not constitute an offer, solicitation or sale of any security in the public offering or concurrent private placement in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s lead PDC therapeutic, CLR 131, is currently in two clinical studies. The CLOVER-1 Phase 2 study and the Phase 1 pediatric safety study. The CLOVER-1 study met the primary efficacy endpoints from the Part A dose-exploration portion, conducted in r/r B-cell malignancies, and is now enrolling in expansion cohorts evaluating in triple class refractory multiple myeloma and BTK inhibitor failed Waldenstrom’s macroglobulinemia patients. The dosing regimen is designed to provide the optimal dose identified in Part A of >60 mCi total body dose. The data from the Part A portion were announced on February 19, 2020.

The Phase 1 pediatric study is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of CLR 131 in children and adolescents with relapsed or refractory cancers, including malignant brain tumors, neuroblastoma, sarcomas, and lymphomas (including Hodgkin’s lymphoma). The Phase 1 study is being conducted internationally at seven leading pediatric cancer centers.

The company’s product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Forward-Looking Statement Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for CLR 131, the volatile market for priority review vouchers, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2019, our Form 10-Q for the quarter ended March 31, 2020, our Form 10-Q for the quarter ended June 30, 2020 and our Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Contacts

Investors:

Monique Kosse
Managing Director
LifeSci Advisors, LLC
646-915-3820
[email protected]



MindBeacon Holdings Inc. Completes Initial Public Offering


Not for distribution to U.S. news wire services or dissemination in the United States

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — MindBeacon Holdings Inc. (“MindBeacon” or the “Company”) (TSX: MBCN) announced today the successful closing of its previously announced initial public offering (the “Offering”) pursuant to which it and TELUS Corporation, 1930339 Ontario Inc., 2451585 Ontario Inc. and 1964998 Ontario Inc. (the “Selling Shareholders”) sold an aggregate of 9,343,750 common shares at a price of $8.00 per share, for total gross proceeds of $74,750,000. The Offering includes the exercise in full by the Underwriters (as defined below) of their over-allotment option to acquire 1,218,750 additional shares of the Company from the Selling Shareholders. The Company received gross proceeds of $65,000,000 and the Selling Shareholders received gross proceeds of $9,750,000.

MindBeacon will use the net proceeds received by it from the Offering to strengthen its financial position and allow it to pursue its growth strategies, which include growing its consumer base and enterprise membership in existing markets and expanding into new geographies, expanding use cases and its continuum of care, building and implementing its BEACON in a Box product offering, investing in artificial intelligence and machine learning, and to fund working capital and other general corporate activities.

The common shares of the Company are listed on the Toronto Stock Exchange under the symbol “MBCN”.

The Offering was made by TD Securities Inc. and Credit Suisse Securities (Canada), Inc. as joint bookrunners, Canaccord Genuity Corp. as co-lead underwriter and Bloom Burton Securities Inc., Beacon Securities Limited and Echelon Wealth Partners Inc. as underwriters.

No securities regulatory authority has either approved or disapproved the contents of this news release. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities of MindBeacon in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered, sold or delivered, directly or indirectly, in the United States (as defined in Regulation S under the U.S. Securities Act). Accordingly, the securities may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws.

About MindBeacon

Established in 2015 through a partnership with CBT Associates, a psychologist-led private clinic specializing in evidence-based therapy including CBT, MindBeacon is developing a comprehensive continuum of mental health offerings through our online BEACON platform (“BEACON”) and in-clinic care. BEACON launched in 2017 as one of the first commercially available, digitally-native platforms offering therapist-assisted internet-based CBT in Canada. MindBeacon is using data to develop mental health programs that are designed to address an individual’s unique needs with effective, affordable and accessible therapy. With a protocol-driven therapeutic approach and the ability to deliver therapy through a team of regulated mental health professionals, BEACON is growing and is changing the therapy landscape. MindBeacon aims to provide a comprehensive and accessible service offering to support clients throughout their journey to better mental health.


Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws, including, without limitation, statements regarding the anticipated use of the net proceeds of the Offering and the execution of the Company’s growth strategy. Forward-looking information can, but may not always, be identified by the use of words such as “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “intend”, “could”, “might”, “would”, “should”, “believe”, and similar references to future periods or the negatives of these words and expressions. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that the Company considered appropriate and reasonable as of the date such statements are made, and is subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk factors identified under “Risk Factors” in the Company’s supplemented PREP prospectus dated December 17, 2020, and in other filings that the Company has made and may make in the future with applicable securities authorities, all of which are available under the Company’s SEDAR profile at www.sedar.com. If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking information is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this news release represents the Company’s expectations as of the date hereof, and is subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws. All of the forward-looking information contained in this news release is expressly qualified by the foregoing cautionary statements.

For further information:

Investor relations

David Galison
(t): (647) 618-2709
(e): [email protected]

Media Relations

(e): [email protected] 



Gritstone Oncology Announces $110 Million Private Placement

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to raise gross proceeds of $110 million resulting from the sale of shares of its common stock and/or pre-funded warrants through a private investment in public equity (PIPE) financing at a price per share of $3.34. The financing was led by certain existing and new investors, Redmile Group, Avidity Partners and EcoR1 Capital.

The PIPE financing is subject to customary closing conditions and is expected to close on December 28, 2020. The PIPE financing was done in compliance with applicable Nasdaq rules and priced at the “Minimum Price” (as defined in the Nasdaq rules). Cowen served as the sole placement agent for the financing. The company expects to use net proceeds from this private placement to fund research and development expenses, including the clinical development of its lead cancer immunotherapies, GRANITE and SLATE, and advancement of opportunities from its core technologies including Gritstone EDGE™ and vaccine platforms, as well as for working capital and other general corporate purposes.

“We believe these additional resources position us well to accelerate the advancement of our two lead cancer immunotherapies, GRANITE and SLATE,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology. “Additionally, we are exploring the broader potential of our first-in-class technology platforms – EDGE™ as a leading T cell antigen identification technology complementing our highly immunogenic vaccine platforms, now well established in human clinical studies.”

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the U.S. except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Gritstone has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Gritstone Oncology

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Gritstone Forward-Looking
Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; and the timing and expectation of the closing of the PIPE financing. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on November 5, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.


Contacts


Media:
Dan Budwick
1AB
(973) 271-6085 
[email protected]

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
[email protected]



Trillium Gold Receives Rivard Property Drill Permit and Files Gold Centre and Leo Drill Permit Applications

PR Newswire

  • Drilling to commence early in the New Year
  • Second rig already mobilized and on the property
  • Testing the intersections of Rivard high-grade gold veins and the Newman Todd structure
  • Drill permit applications made for both Gold Centre and the Leo project

VANCOUVER, BC, Dec. 23, 2020 /PRNewswire/ – Trillium Gold Mines Inc. (TSXV: TGM) (OTCQX: TGLDF) (FRA: 0702) (“Trillium” or the “Company”) is pleased to announce it has received its drill permit for the Rivard property, southwest part of the Newman Todd project, located in Red Lake, Ontario. A second diamond drill has already been mobilized to site and preparations are underway to begin drilling on the Rivard property as part of the drill program now in progress on the Newman Todd project. The drilling on Rivard will focus on testing a structural corridor, containing high-grade gold veins, both along strike and at depth and determine its impact on the Newman Todd Structure to the east.

Russell Starr, CEO of Trillium Gold comments “Receiving the drill permit for Rivard is an exciting moment for Trillium Gold and our shareholders and is the beginning of several drill permits to come. The Rivard Property, which covers part of the southwest extension of Newman Todd, has high grade visible gold at surface throughout property and has yet to be drilled in any meaningful way. The opportunity to drill the intersection of Rivard’s high-grade gold bearing veins and the Newman Todd structure and should create tremendous value for all our shareholders.”

Permit applications have also been made for the Gold Centre property, immediately adjacent, and along strike of Evolution Mining’s Red Lake Mine and the Leo Property, approximately 40 km south of Red Lake. While the dates for obtaining these permits is not known, ultra-deep surface drilling is being planned for the Gold Centre Property that will confirm the Balmer volcanic rocks, previously intersected by Rupert Resources, and test for Red Lake Mine mineralization on the Gold Centre Property. Preparations are underway for a dual-purpose overburden and bedrock drilling program, to begin early in 2021, on the Leo Property.

William Paterson, Trillium Gold’s Vice President of Exploration comments, “I am glad for the Rivard permit and am really looking forward to testing the high-grade gold veins that have seen considerable historical shallow trench testing. We believe these veins have a significant impact on the Newman Todd Zone. I am also anticipating beginning exploration work on both the Leo and Gold Centre Properties once those permits have been received.”

The technical information presented in this news release has been reviewed and approved by William Paterson QP, PGeo, VP of Exploration of Trillium Gold Mines, as defined by NI 43-101.

On behalf of the Board of Directors,

Trillium Gold Mines Inc.

“Russell
 
Starr”

Russell Starr

President, CEO and Director

About
 
Trillium
 
Gold
 
Mines
 
Inc
.
Trillium Gold Mines Inc. is a British Columbia based company engaged in the business of acquisition, exploration and development of mineral properties located in the highly prospective Red Lake Mining District of Northern Ontario.

Disclosure and CautionNeither

TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/trillium-gold-receives-rivard-property-drill-permit-and-files-gold-centre-and-leo-drill-permit-applications-301197918.html

SOURCE Trillium Gold Mines Inc.

Thinking about buying stock in Ocugen, Kopin Corp, Mogo Inc, Supernus Pharmaceuticals, or eMagin Corp?

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for OCGN, KOPN, MOGO, SUPN, and EMAN.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-ocugen-kopin-corp-mogo-inc-supernus-pharmaceuticals-or-emagin-corp-301198088.html

SOURCE InvestorsObserver

Caesars Entertainment, Inc. Completes Previously Announced Sale of Eldorado Resort Casino Shreveport to Bally’s Corporation

PR Newswire

RENO, Nev. and LAS VEGAS, Dec. 23, 2020 /PRNewswire/ — Caesars Entertainment, Inc. (NASDAQ: CZR) (“Caesars” or “CZR”) today announced the closing of the sale of Eldorado Resort Casino Shreveport to Bally’s Corporation for $140 million in net proceeds, subject to a customary working capital adjustment.  

“The completion of the sale of Eldorado Resort Casino Shreveport satisfies the Federal Trade Commission request to divest the asset in connection with the Caesars-Eldorado transaction which closed earlier this year,” said Tom Reeg, CEO of Caesars Entertainment, Inc. “Since our acquisition of the property fifteen years ago, our Team Members’ passion and commitment have driven our success in Shreveport.  We wish all of them continued success under Bally’s ownership.”

Macquarie Capital and Milbank LLP represented Caesars Entertainment on the transaction.        

About Caesars Entertainment, Inc.
Caesars Entertainment, Inc. (NASDAQ: CZR) is the largest casino-entertainment company in the U.S. and one of the world’s most diversified casino-entertainment providers. Since its beginning in Reno, Nevada, in 1937, Caesars Entertainment has grown through development of new resorts, expansions and acquisitions. Caesars Entertainment’s resorts operate primarily under the Caesars®, Harrah’s®, Horseshoe® and Eldorado® brand names. Caesars Entertainment offers diversified amenities and one-of-a-kind destinations, with a focus on building loyalty and value with its guests through a unique combination of impeccable service, operational excellence and technology leadership. Caesars Entertainment is committed to its employees, suppliers, communities and the environment through its PEOPLE PLANET PLAY framework. For more information, please visit www.caesars.com/corporate.

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words “anticipates,” “assumes,” “believes,” “estimates,” “expects,” “guidance,” “intends,” “plans,” “projects,” and similar expressions that do not relate to historical matters. All statements other than statements of historical fact are forward-looking statements. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors which are, in some cases, beyond Caesars’ control and could materially affect actual results, performance, or achievements.

Although Caesars believes that in making such forward-looking statements its expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected.  Caesars cannot assure you that the assumptions upon which these statements are based will prove to have been correct. Important risk factors that may affect their respective business, results of operations and financial position are detailed from time to time in Caesars’  filings with the Securities and Exchange Commission. Caesars does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/caesars-entertainment-inc-completes-previously-announced-sale-of-eldorado-resort-casino-shreveport-to-ballys-corporation-301197860.html

SOURCE Caesars Entertainment, Inc.